BACKGROUND:Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies. METHODS: We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of three groups. In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 weeks (the lead-in period). Subsequently, group 1 (the control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 24 weeks, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an additional 20 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks. Nonblack patients and black patients were enrolled and analyzed separately. RESULTS:A total of 938 nonblack and 159 black patients were treated. In the nonblack cohort, a sustained virologic response was achieved in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients (67%) in group 2 (P<0.001), and in 213 of the 311 patients (68%) in group 3 (P<0.001). In the black cohort, a sustained virologic response was achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in group 2 (P=0.04), and in 29 of the 55 patients (53%) in group 3 (P=0.004). In group 2, a total of 44% of patients received peginterferon-ribavirin for 28 weeks. Anemia led to dose reductions in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, respectively. CONCLUSIONS: The addition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection. The rates were similar with 24 weeks and 44 weeks of boceprevir. (Funded by Schering-Plough [now Merck]; SPRINT-2 ClinicalTrials.gov number, NCT00705432.).
RCT Entities:
BACKGROUND:Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies. METHODS: We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of three groups. In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 weeks (the lead-in period). Subsequently, group 1 (the control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 24 weeks, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an additional 20 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks. Nonblack patients and black patients were enrolled and analyzed separately. RESULTS: A total of 938 nonblack and 159 black patients were treated. In the nonblack cohort, a sustained virologic response was achieved in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients (67%) in group 2 (P<0.001), and in 213 of the 311 patients (68%) in group 3 (P<0.001). In the black cohort, a sustained virologic response was achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in group 2 (P=0.04), and in 29 of the 55 patients (53%) in group 3 (P=0.004). In group 2, a total of 44% of patients received peginterferon-ribavirin for 28 weeks. Anemia led to dose reductions in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, respectively. CONCLUSIONS: The addition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection. The rates were similar with 24 weeks and 44 weeks of boceprevir. (Funded by Schering-Plough [now Merck]; SPRINT-2 ClinicalTrials.gov number, NCT00705432.).
Authors: W Jessner; M Gschwantler; P Steindl-Munda; H Hofer; T Watkins-Riedel; F Wrba; C Mueller; A Gangl; P Ferenci Journal: Lancet Date: 2001-10-13 Impact factor: 79.321
Authors: Srikanth Venkatraman; Stéphane L Bogen; Ashok Arasappan; Frank Bennett; Kevin Chen; Edwin Jao; Yi-Tsung Liu; Raymond Lovey; Siska Hendrata; Yuhua Huang; Weidong Pan; Tejal Parekh; Patrick Pinto; Veljko Popov; Russel Pike; Sumei Ruan; Bama Santhanam; Bancha Vibulbhan; Wanli Wu; Weiying Yang; Jianshe Kong; Xiang Liang; Jesse Wong; Rong Liu; Nancy Butkiewicz; Robert Chase; Andrea Hart; Sony Agrawal; Paul Ingravallo; John Pichardo; Rong Kong; Bahige Baroudy; Bruce Malcolm; Zhuyan Guo; Andrew Prongay; Vincent Madison; Lisa Broske; Xiaoming Cui; Kuo-Chi Cheng; Yunsheng Hsieh; Jean-Marc Brisson; Danial Prelusky; Walter Korfmacher; Ronald White; Susan Bogdanowich-Knipp; Anastasia Pavlovsky; Prudence Bradley; Anil K Saksena; Ashit Ganguly; John Piwinski; Viyyoor Girijavallabhan; F George Njoroge Journal: J Med Chem Date: 2006-10-05 Impact factor: 7.446
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich Journal: N Engl J Med Date: 2004-07-29 Impact factor: 91.245
Authors: Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst Journal: N Engl J Med Date: 2004-07-29 Impact factor: 91.245
Authors: Daniel John Smyth; Duncan Webster; Lisa Barrett; Mark MacMillan; Lisa McKnight; Frank Schweiger Journal: Can J Gastroenterol Hepatol Date: 2014-11
Authors: Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond Journal: Virology Date: 2011-11-12 Impact factor: 3.616
Authors: Andrew H Talal; Rositsa B Dimova; Randy Seewald; Raymond H Peterson; Marija Zeremski; David C Perlman; Don C Des Jarlais Journal: J Subst Abuse Treat Date: 2012-03-08
Authors: Cassandra B Jabara; Fengyu Hu; Katie R Mollan; Sara E Williford; Prema Menezes; Yan Yang; Joseph J Eron; Michael W Fried; Michael G Hudgens; Corbin D Jones; Ronald Swanstrom; Stanley M Lemon Journal: Antimicrob Agents Chemother Date: 2014-08-04 Impact factor: 5.191
Authors: Runyan Jin; Ling Cai; Ming Tan; John G McHutchison; Thomas C Dowling; Charles D Howell Journal: Am J Gastroenterol Date: 2012-10-23 Impact factor: 10.864